News & Updates

A recent first-in-human study has shown that directly applying pembrolizumab to the bladder is a safe and effective treatment option for patients with nonmuscle-invasive bladder cancer (NMIBC) who are unresponsive to bacillus Calmette-Guérin (BCG) treatment.

Trabectedin did not improve overall survival (OS) or progression-free survival (PFS) compared with chemotherapy in women with recurrent ovarian, primary peritoneal, or fallopian tube cancer and BRCA mutation or BRCAness phenotypes, according to results of the phase III MITO23 trial.

All intravenous (IV) and subcutaneous (SC) doses of the monoclonal antibody combination of casirivimab plus imdevimab effectively reduces viral load in COVID-19 patients with asymptomatic or low-risk symptomatic infection, according to the results of a phase II study.

Topical pharmacological treatment combinations, chemical peels, and photochemical therapy are deemed to be the best and the most effective options for mild-to-moderate acne vulgaris.

In the treatment of patients with organic disease and heavy menstrual bleeding and/or dysmenorrhea, the use of levonorgestrel-releasing intrauterine system (LNG-IUS) attenuates chronic pelvic pain, according to a study. However, it appears to confer an increased risk of expulsion for some women.

The use of most types of fertility drugs does not appear to put infertile women at risk of developing colorectal cancer, according to a study.